Cergentis
Erik Splinter has, both at the Erasmus MC and the Hubrecht Institute, worked extensively on the development and optimisation of technologies for the analysis of 3D structures of human genomes. He has co-authored peer-reviewed publications in, among others, Genes & Development, Molecular Cell, and Nature Genetics.
At Cergentis, in his role as CTO, Erik is primarily responsible for the further development of the TLA technology and its various applications.
This person is not in any teams
This person is not in any offices
Cergentis
1 followers
Cergentis' Targeted Locus Amplification (TLA) Technology uniquely enables the targeted complete Next Generation Sequencing of any genomic locus in any genome of interest.